39株指/趾甲分离黄曲霉复合体(Aspergillus section Flavi)菌种鉴定和抗真菌药物敏感性

中国真菌学杂志　 2021, Vol. 16 　Issue (4): 222-228.

39株指/趾甲分离黄曲霉复合体(Aspergillus section Flavi)菌种鉴定和抗真菌药物敏感性

许雪¹, 邓淑文¹, 王晓东², 赵蓉芬¹, 张虹¹, 于农¹, Mohammad Javad Najafzadeh³, 史冬梅⁴, 陆敏¹

1. 苏州高新区人民医院检验科, 苏州 215000;
2. 新疆医科大学第一附属医院皮肤科, 乌鲁木齐 830011;
3. Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
4. 山东济宁市第一人民医院皮肤科/医学真菌学实验室, 济宁 272000

收稿日期:2020-08-17 发布日期:2021-08-31
通讯作者: 陆敏,E-mail:940910359@qq.com;史冬梅,E-mail:shidongmei28@163.com E-mail:940910359@qq.com;shidongmei28@163.com
作者简介:许雪,女(汉族),硕士,实习研究员.E-mail:xuxue2113@163.com;邓淑文,女(汉族),博士,主任技师.E-mail:danyanghhh@qq.com
基金资助:
苏州市科委临床重点诊疗技术专项（LCZX201728）；苏州高新区卫计局重点项目（2017Z008）；国家自然科学基金国际合作项目（81720100826）

Species identification and in vitro antifungal susceptibility profile of 39 isolates of Aspergillus section Flavi isolated from nails in Iran

XU Xue¹, DENG Shuwen¹, WANG Xiaodong², ZHAO Rongfen¹, ZHANG Hong¹, YU Nong¹, Mohammad Javad Najafzadeh³, SHI Dongmei⁴, LU Min¹

1. Department of Medical Microbiology, The People's Hospital of Suzhou New District, Suzhou 215000, China;
2. Department of Dermatology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China;
3. Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
4. Department of Dermatology&Laboratory of Medical Mycology, Jining, First People's Hospital, Jining 272000, China

Received:2020-08-17 Published:2021-08-31

摘要/Abstract

摘要： 目的对来自伊朗马什哈德地区（Mashhad，Iran）甲真菌病患者指/趾甲分离的39株黄曲霉复合体（Aspergillus section Flavi）菌株进行菌种鉴定及抗真菌药物敏感性研究。方法菌种鉴定采用β-tubulin/calmodulin基因测序的分子鉴定联合MALDI-TOF质谱鉴定；体外药物敏感性试验参照CLSI M38-A3方案检测包括特比萘芬、新三唑类药物、棘白菌素类等10种抗真菌药物。结果基于形态学鉴定的39株黄曲霉复合体（Aspergillus section Flavi）菌株中，分子鉴定结果表明38株为Aspergillus flavus （A. flavus）/Aspergillus oryzae （A. oryzae），1株为Aspergillus minisclerotigenes （A. minisclerotigenes）。对38株分子鉴定为A. flavus/A. oryzae菌株采用MALDI-TOF质谱鉴定结果为A. flavus，而MALDI-TOF质谱错误鉴定同形菌种A. minisclerotigenes为A. flavus。抗真菌药物敏感性结果表明，特比萘芬、泊沙康唑和棘白菌素类药物对黄曲霉复合体（Aspergillus section Flavi）菌种均具有抗真菌活性。结论分子鉴定联合MALDI-TOF质谱鉴定可准确鉴定黄曲霉复合体菌株到菌种水平，特别是分子鉴定不能区分A. flavus/A. oryzae，而MALDI-TOF鉴定可将二者区分。完善参考菌种数据库是MALDI-TOF质谱准确鉴定的关键。特比萘芬、泊沙康唑和棘白菌素类药物可作为治疗黄曲霉复合体（Aspergillus section Flavi）菌种所致甲真菌病的潜在有效药物。

关键词: 非皮肤癣菌丝状真菌(NDM), 非皮肤癣菌丝状菌甲真菌病(NDMO), 黄曲霉复合体(Aspergillus section Flavi), 分子鉴定, MALDI-TOF质谱, 抗真菌活性, 伊朗

Abstract: Objective In this study, species identification and in vitro antifungal susceptibility profile of 39 isolates of Aspergillus section Flavi isolated from onychomycosis in Mashhad, Iran were investigated. Methods β-tubulin/calmodulin gene sequencing combined with MALDI-TOF MS were used for identification of 39 isolates of Aspergillus section Flavi; Antifungal susceptibility to 10 antifungal drugs including terbinafine, new triazole and echinocandins were determined on all the isolates according to CLSI M38-A3. Results Among the 39 Aspergillus section Flavi based on morphological identification, 38 isolates were identified as A. flavus or A. oryzae by molecular method, and identified as A. flavus by MALDI-TOF MS, one isolate was A. minisclerotigenes by molecular method. However, MALDI-TOF MS misidentified one isolate of A.minisclerogenes as A.flavus. The antifungal susceptibility results indicated that terbinafine, posaconazole and echinocandins had good activity against the most Aspergillus isolates tested in this study. Conclusions Molecular identification combined with MALDI-TOF MS could correctly identify Aspergillus section Flavi to species level, particularly for A. flavus/A. oryzae which molecular identification could not differentiated, MALDI-TOF MS could identify correctly. Expanding reference strain database is necessary for precise identification of Aspergillus section Flavito species level. Terbinafine, posaconazole and echinocandins could be potentially effective drugs for the treatment of onycomycosis due to Aspergillus section Flavi.

Key words: non-dermatophytes mold, non-dermatophyte molds onychomycosis, Aspergillus section Flavi, molecular identification, MALDI-TOF-MS, antifungal susceptibility, Iran

中图分类号:

许雪, 邓淑文, 王晓东, 赵蓉芬, 张虹, 于农, Mohammad Javad Najafzadeh, 史冬梅, 陆敏. 39株指/趾甲分离黄曲霉复合体(Aspergillus section Flavi)菌种鉴定和抗真菌药物敏感性[J]. 中国真菌学杂志, 2021, 16(4): 222-228.

XU Xue, DENG Shuwen, WANG Xiaodong, ZHAO Rongfen, ZHANG Hong, YU Nong, Mohammad Javad Najafzadeh, SHI Dongmei, LU Min. Species identification and in vitro antifungal susceptibility profile of 39 isolates of Aspergillus section Flavi isolated from nails in Iran[J]. Chinese Journal of Mycology, 2021, 16(4): 222-228.

参考文献

[1] Motamedi M, Ghasemi Z, Shidfar MR, et al. Growing incidence of non-dermatophyte onychomycosis in Tehran, Iran[J]. Jundishapur J Microbiol, 2016, 9(8):e40543.
[2] Nouripour-Sisakht S, Mirhendi H, Shidfar MR, et al. Aspergillus species as emerging causative agents of onychomycosis[J]. J Mycol Med, 2015, 25(2):101-107.
[3] Bongomin F, Batac CR, Richardson MD, et al. A review of onychomycosis due to Aspergillus species[J]. Mycopathologia, 2018, 183(3):485-493.
[4] Mehta M, Sharma J, Bhardwaj SB. Proximal subungual onychomycosis of digitus minimus due to Aspergillus brasiliensis[J]. Pan Afr Med J, 2020, 35:79.
[5] Zotti M, Agnoletti AF, Vizzini A, et al. Onychomycosis from Aspergillus melleus, a novel pathogen for humans. fungal identification and in vitro drug susceptibility[J]. Exp Dermatol, 2015, 24(12):966-968.
[6] Samson RA, Noonim P, Meijer M, et al. Diagnostic tools to identify black aspergilli[J]. Stud Mycol, 2007, 59:129-145.
[7] Sanguinetti M, Posteraro B. MALDI-TOF mass spectrometry:any use for Aspergilli[J]? Mycopathologia, 2014, 178(5-6):417-426.
[8] Sanguinetti M, Posteraro B. Identification of Molds by matrix-assisted laser desorption ionization-time of flight mass spectrometry[J]. J Clin Microbiol, 2017, 55(2):369-379.
[9] Chang PK, Ehrlich KC. What does genetic diversity of Aspergillus flavus tell us about Aspergillus oryzae[J]? Int J Food Microbiol, 2010, 138(3):189-199.
[10] Velegraki A, Kambouris M, Kostourou A, et al. Rapid extraction of fungal DNA from clinical samples for PCR amplification[J]. Med Mycol, 1999, 37(1):69-73.
[11] Wayne P. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. Approved standard. CLSI document M38-A3[S]. Clinical and Laboratory Standards Institute, 2017.
[12] Chadeganipour M, Nilipour S, Ahmadi G. Study of onychomycosis in Isfahan, Iran[J]. Mycoses, 2010, 53(2):153-157.
[13] Hashemi SJ, Gerami M, Zibafar E, et al. Onychomycosis in Tehran:mycological study of 504 patients[J]. Mycoses, 2010, 53(3):251-255.
[14] Mikaeili A, Karimi I. The incidence of onychomycosis infection among patients referred to hospitals in Kermanshah Province, Western Iran[J]. Iran J Public Health, 2013, 42(3):320-325.
[15] Hedayati MT, Pasqualotto AC, Warn PA, et al. Aspergillus flavus:human pathogen, allergen and mycotoxin producer[J]. Microbiology, 2007, 153(Pt 6):1677-1692.
[16] Pildain MB, Frisvad JC, Vaamonde G, et al. Two novel aflatoxin-producing Aspergillus species from Argentinean peanuts[J]. Int J Syst Evol Microbiol, 2008, 58(Pt 3):725-735.
[17] Dehghan P, Bui T, Campbell LT, et al. Multilocus variable-number tandem-repeat analysis of clinical isolates of Aspergillus flavus from Iran reveals the first cases of Aspergillus minisclerotigenes associated with human infection[J]. BMC Infect Dis, 2014, 14:358.
[18] Karimizadeh Esfahani M, Eslampoor A, Dolatabadi S, et al. First case of fungal keratitis due to Aspergillus minisclerotigenes in Iran[J]. Curr Med Mycol, 2019, 5(2):45-48.
[19] Frisvad JC, Hubka V, Ezekiel CN, et al. Taxonomy of Aspergillus section Flavi and their production of aflatoxins, ochratoxins and other mycotoxins[J]. Stud Mycol, 2019, 93:1-63.
[20] Schmitt HJ, Bernard EM, Andrade J, et al. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp[J]. Antimicrob Agents Chemother, 1988, 32(5):780-781.
[21] Moore CB, Walls CM, Denning DW. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B[J]. Antimicrob Agents Chemother, 2001, 45(6):1882-1885.
[22] Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.:34 cases treated with weekly intermittent terbinafine[J]. Dermatology, 2004, 209(2):104-110.
[23] Wayne P. Reformance standards for antifungal susceptibility testing of filamentous fungi, 1 st ed. CLSI document M61[S]. Clinical and Laboratory Standards Institute, 2017.
[24] Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species[J]. J Clin Microbiol, 2008, 46(8):2568-2572.
[25] Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin:a head-to-head comparison using the CLSI M38-A2 broth microdilution method[J]. J Clin Microbiol, 2009, 47(10):3323-3325.